Compare Johnson & Johnson (JNJ) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Kimberly Clark Corp — how do they compare? Johnson & Johnson trades at $250.05 (market cap $598.96B), while Kimberly Clark Corp trades at $107.5 (market cap $36.01B). The key difference: Johnson & Johnson is far larger — about 16.6× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| JNJ | KMB | |
|---|---|---|
Market Cap | $598.96B | $36.01B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Staples |
52-Week High | $267.24 | $136.77 |
52-Week Low | $164.36 | $93.05 |
Enterprise Value | $631.90B | $42.55B |
Dividend Yield | 2.15% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Kimberly-Clark (KMB) trades at $108.43, up 0.07% on the day, with a neutral technical signal and bullish moving averages. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.97 exceeding the $1.93 estimate. Revenue declined to $16.45B in 2025, but net income margin remains strong at 12.8%. Recent news highlights KMB's innovation strategy and its status as a Dividend King, with a 4.5% yield attracting income investors.
KMB offers stable income with a high dividend yield and solid fundamentals, but faces revenue pressure and competitive risks. Analyst consensus is a $115.33 price target with a hold-heavy rating. Key risks include consumer sentiment impacts and input cost inflation, while the pending Kenvue merger provides growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
